Tiffany & Co (NYSE:TIF)

Tiffany director James Lillie snapped up $480,095 shares in the luxury jewelry retailer on March 27. Lillie- a top-performing insider- now boasts a total shareholding of well over $2.1 million TIF shares. We can’t know his motive, but we can see that his move came on the back of TIF’s solid fourth quarter results and updated 2018 guidance. Boosted by a lower-than-expected tax rate, earnings of $1.71 easily beat the Street’s forecasted estimate of $1.63.

Indeed, top Oppenheimer analyst Brian Nagel is also upbeat about TIF’s longer-term path ahead. He reiterated his Buy rating on March 16 with a $105 price target. According to Nagel, “Tiffany represents one of the best-managed and most-dominant brands among leading international retailers.”

Specifically, Nagel is placing his faith in Tiffany’s new CEO Alessandro Bogliolo. Crucially, Bogliolo is trying to more aggressively build the Tiffany franchise through strategic priorities like accelerating new product introductions and digital operations. “We view this decision as a key measure in unlocking a much awaited and sustainable top-line jolt for the chain” concludes Nagel.

Overall our data reveals that from top analysts alone Tiffany has 100% support right now. Plus the $117.50 average price target of these analysts indicates 22% upside potential from current levels.

(Click on image to enlarge)

Ollie’s Bargain Outlet Holding (Nasdaq:OLLI)

Shares in this huge discount retailer are crushing the market. In the last year, prices exploded from $33 to $60 on OLLI’s continued strong execution, brand identity and limited competition prospects.

So it’s not surprising that during the last three months, insiders have been busy snapping up shares worth over $1 million. This includes multiple informative buy transactions from top insiders including Senior VP Kevin McLain($355,290) and Executive VP John Swygert ($324,000). Both these insiders have a five-star rating for the success rate and average return of their transactions.

Most notably, the stock also has the support of the #2 best analyst on TipRanks, RBC’s Gerard Cassidy. He gives this bullish analysis of OLLI’s prospects:

“With projected annual store growth of ~15%, which is 50– 100% higher than many other “high store growth” retailers in the 8–10% range, and the potential to expand by 4x from current levels (268 to 950+ over time), we think Ollie’s has one of the best long-term store growth profiles in the Hardlines/Broadlines Retail sector.”

These stores currently generate ‘extremely strong cash-on-cash returns of 50%+’. And don’t worry about the e-commerce threat- Cassidy points out that the stores are insulated by the constantly changing/treasure hunt-oriented shopping experience, and steep clearance-level prices.

In total, this ‘Strong Buy’ stock boasts four recent buy ratings from top analysts with an average analyst price target of $61.50. The highest price target of $71 (19% upside potential) comes from Piper Jaffray’s Peter Keith.

(Click on image to enlarge)

Adaptimmune Therapeutics (Nasdaq:ADAP)

This UK-based stock is buzzing right now. Adaptimmune is working to transform cancer treatment with its novel immunotherapies. Shares have soared almost 50% in the last three months on very promising early results of its SPEAR T-cell therapy. One case saw a patient’s tumor in his shoulder shrink by nearly half over four weeks.

“Results in a 2nd solid tumor strengthens our conviction that our pipeline of unique TCRs will be capable of addressing multiple solid tumors,” states Adaptimmune’s chief medical officer Rafael Amado. Indeed, in just 1-week insiders have bought a total of $23 million of ADAP shares. This includes owner Forest Baskett who has a whopping $819 million invested in the stock.

From a Street perspective, Raymond James analyst Reni Benjamin is certainly feeling the heat. “We are maintaining our Outperform rating and increasing our price target to $20 (up from $11) for ADAP given our increasing confidence in the company’s TCR franchise,” he writes on March 16. For Benjamin, these “encouraging” results indicate that “high-level responses can be achieved by a TCR product in solid tumors. This could ultimately translate into improved survival outcomes.” Plus with a marquee partner like GlaxoSmithKline and a strong cash position of $188 million (pro forma), Adaptimmune has a lot going for it right now.

In the last week, our data shows that three analysts have published buy ratings on Adaptimmune. These analysts see the stock hitting $17.50 (73% upside potential from the current share price).

(Click on image to enlarge)